RESEARCH TRIANGLE PARK -- MCNC, an independent nonprofit organization that employs advanced networking technologies and systems to continuously improve learning and collaboration throughout North Carolina's K-20 education community has opened online registration for its North Carolina Research and Education Network Community Celebration Dec. 3-4 at www.mcnc.org.
The event will be held at the SAS Worldwide Headquarters in Cary. Registration closes Nov. 30. You can register online.
Former Gov. Jim Hunt will be the keynote speaker Dec. 3.
The event provides an opportunity to hear from leaders in the community and share applications, best practices, successes, and ideas experienced by peers through the use of NCREN and its related services.
NCREN is one of the nation's first statewide education and research networks.
AT T expands 3G network here
DURHAM -- As part of its continuing network investment to support growing demand for advanced mobile devices and applications, AT&T* today announced the activation of a new 3G cell site in Durham that will enhance coverage for students and facility at Duke University.
The new cell site is part of AT&T's ongoing efforts to drive innovation and extend its 3G wireless network -- the fastest in the nation, according to independent testing. It is also part of AT&T's ongoing investment to build the broadband networks that will fuel economic growth and create jobs, and enable the its customers to quickly access the content, applications and services that matter most to them.
Inspire pitches new treatment
MINNEAPOLIS, Minn. -- New data presented Thursday at the 23rd Annual North American Cystic Fibrosis Conference here by Durham-based pharmaceutical company Inspire, underscored the need for early intervention disease- modifying therapies that may reduce the need for multiple pharmacological treatments.
For the first time, therapies that aim to treat the basic genetic defect in CF have reached Phase 3 clinical trials and Inspire's denufosol were among those highlighted at NACFC.
Denufosol is a first-in-class treatment and the only in late-stage trials targeting an underlying ion transport defect present in all CF patients.
E-mail business news of interest to our readers to Monica Chen at mchen@heraldsun.com, or call (919) 419-6636.
